Navigation Links
Mylan's Third Quarter 2011 Adjusted Diluted EPS Increases 28% to $0.55
Date:10/26/2011

sociated with the 2017, 2018 and 2020 Senior Notes debt offerings completed in 2010. Included in interest expense for the current quarter and the comparable prior year period are $36.8 million and $42.0 million, primarily related to the amortization of the discounts on our convertible debt instruments and 2018 Senior Notes, net of amortization of the premium on our 2020 Senior Notes.

Other income (expense), net, for the current nine-month period was income of $22.5 million compared to expense of $29.4 million in the comparable prior year period.  In addition to the items discussed above, included in other income (expense), net, for the comparable prior year period are charges associated with the termination of certain interest rate swaps totaling $7.4 million and the write-off of previously deferred financing fees of $7.6 million, in conjunction with the debt offering completed during the nine months ended September 30, 2010.

EBITDA was $1.17 billion for the nine months ended September 30, 2011, and $910.9 million for the comparable prior year period.  After adjusting for certain items as further detailed below, adjusted EBITDA was $1.27 billion for the current nine-month period and $1.03 billion for the comparable prior year period, representing a 24% increase.  

Non-GAAP Financial Measures Mylan is disclosing non-GAAP financial measures when providing financial results. Primarily due to acquisitions, Mylan believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition to disclosing its financial results determined in accordance with GAAP, Mylan is disclosing non-GAAP results that exclude items such as amortization expense and other costs directly associa
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
2. Life Technologies Announces Third Quarter 2011 Results
3. Insmed to Host 2011 Third Quarter Earnings Conference Call
4. Cell Therapeutics, Inc. (CTI) Reports Third Quarter Financial Results and Milestones
5. Anthera Announces Third Quarter 2011 Financial Report and Conference Call
6. Pacira Pharmaceuticals, Inc. Announces Timing for Third Quarter 2011 Financial Results Webcast and Conference Call
7. Amgen’s Third Quarter 2011 Revenue and Adjusted Earnings Per Share (EPS) Each Increased 3 Percent to $3.9 Billion and $1.40
8. HeartWare Schedules Third Quarter Conference Call and Webcast
9. Dyadic International Announces Date and Time of Third Quarter 2011 Financial Results Release and Conference Call
10. United Therapeutics Corporation to Announce Third Quarter 2011 Financial Results Before Market Open on Thursday, October 27, 2011
11. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Automotive, a group of car dealerships headquartered in ... Center and offering free oil change coupons for participation in ... 18 at the Bill Jacobs Cadillac and Chevrolet location from ... )  The Bill Jacobs Auto annual blood ...
(Date:1/15/2014)... 15, 2014 Cynvenio, a cancer diagnostics ... the genomic analysis of tumor cells in the bloodstream, ... web-based cancer decision support application powered by CollabRx, Inc. ... ClearID™ genomic test, Therapy Finder will provide breast cancer ...
(Date:1/15/2014)... A study has been launched to test whether ... could help to tackle the problem of obesity.  This unique ... surgery based in Stowmarket) and academics at University Campus Suffolk ... technology, which is inspired by equipment used to collect data ...
(Date:1/15/2014)... DTS Language Services, Inc . is ... for Life Science organizations who need document translations. Clients ... of their documents in advance with a selection of nearly ... translations, often a critical factor in clinical and scientific fields, ...
Breaking Biology Technology:Join the Bill Jacobs Auto blood drive and receive a free oil change 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4DTS Improves Efficiency for Life Science Document Translations 2
... (Nasdaq: FOLD ) today announced it plans to initiate ... drug in development for the treatment of Pompe Disease. ... pharmacokinetics of AT2220 in muscle tissue in healthy adult subjects. ... to Amicus, proposal for the Phase 1 study and subsequently ...
... PARIS, September 30 , ... to Achieve Similar, Well,Tolerated Glycemic Control Versus Lantus(R) , ... ) announced today results of a,head-to-head study providing further evidence ... [rDNA] injection) compared,to twice-daily insulin detemir. The study was presented ...
... John McPherson, Platform Leader, Cancer Genomics and High-Throughput Screening, ... Institute for Cancer Research (OICR) led a team of ... NEBNext(TM) DNA Sample Prep Reagents for use with OICR,s ... evaluation, "We are constantly striving for the best quality ...
Cached Biology Technology:Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 2Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 3Amicus Therapeutics Announces Plan to Initiate Phase 1 Study of AT2220 for Pompe Disease 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 2Superior Efficacy-dose Ratio for Lantus(R) Over detemir 3Superior Efficacy-dose Ratio for Lantus(R) Over detemir 4Superior Efficacy-dose Ratio for Lantus(R) Over detemir 5Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing 2
(Date:7/9/2014)... about the prevalence of antibiotic-resistant illness, Case Western ... to disabling disease: blocking bacteria,s access to iron ... bacterial siderophore, a small molecule, captures iron from ... as well as how the body launches ... findings appear in a recent edition of ...
(Date:7/9/2014)... may be able to cope with the rising salinity of ... Arctic today is best known for its tundra and polar ... to 38 million years ago during what is known as ... huge temperate forest with brackish water, home to a variety ... and giant tortoises. Much of what is known about the ...
(Date:7/9/2014)... but often can be defeated with antibiotics and then ... Now, scientists have built a new weapon against such pathogens ... journal ACS Applied Materials & Interfaces , their study ... them than medicine alone. , David Leong, Jianping Xie and ... undetectable in the human body or in places that antibiotics ...
Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Shark teeth analysis provides detailed new look at Arctic climate change 2Shark teeth analysis provides detailed new look at Arctic climate change 3
... compound found in green tea shows great promise for ... tumors and a deadly congenital disease. The discovery ... Dr. Thomas Smith at The Donald Danforth Plant Science ... Philadelphia. Their findings are published in the recent article, ...
... A research team led by St. Jude Children,s ... for treatment of the childhood eye tumor retinoblastoma. Their ... cancer,s cellular origins are as scrambled as the developmental ... cancers that resemble a particular type of cell, researchers ...
... New research suggests that blood stem cells can be involved ... caused by the abnormal proliferation of mature cells. The study, ... the journal Cancer Cell , may guide future strategies ... CLL is a cancer of a type of mature ...
Cached Biology News:Researchers demonstrate green tea is effective in treating genetic disorder and types of tumors 2Childhood eye tumor made up of hybrid cells with jumbled development 2Childhood eye tumor made up of hybrid cells with jumbled development 3Stem cells central to pathogenesis of mature lymphoid tumors 2
Recombinant Mouse Matrilin-4, CF Protein Family: Extracellular Matrix Molecules, Chondrogenesis Markers...
Request Info...
... labware. Waterproof, moisture-proof film prevents sample ... be folded repeatedly and twisted around ... at 21C (70F), wrapping film increases ... removed, film only partially returns to ...
...
Biology Products: